© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 20, 2019
While better therapies exist to treat patients with heart failure with reduced ejection fraction, there are several hurdles preventing them from being implemented.
Doctors need to use their best judgement when deciding when to use cardiogenic shock devices for temporary mechanical support.
September 18, 2019
How recent trends in heart failure research have shown more priority to patient quality of life outcomes.
How does the broadened sacubitril/valsartan assessment influence the treating confidence of a clinician?
Shaquille O'Neal, EdD, and Elizabeth Ofili, MD, discuss how organizations and physicians are taking novel approaches to engage patients and non-patients about heart failure.
New findings from the trial show daily adherence to the fluid monitoring ReDS system dropped HF patient readmission risk by 58%.
Shaquille O'Neal and Elizabeth Ofili, MD, sit down to discuss Shaq Gets Real, which is a new campaign from Arbor Pharmaceuticals to increase awareness of the disparities in heart failure rates in the African American community.
After success in a recent clinical trial, dapagliflozin will soon be available to reduce the risk of heart failure in adults with heart failure reduced ejection fraction or preserved ejection fraction.
Elizabeth Ofili, MD, discusses the importance of annual meetings, such as HFSA 2019, for outreach and engaging patient populations about heart failure.
September 17, 2019
At the annual meeting dedicated to heart failure, investigators present nutritional recommendations for patients, which includes dietary consultations, bariatric surgery, and a reduction in saturated fats and sodium.
Atopic Dermatitis Severity Linked to Incremental Societal Healthcare Costs
Strong Response Maintenance for Plaque Psoriasis Patients Using Tildrakizumab
Clinical Efficacy, Safety of Brolucizumab Similar to Trial Results for nAMD Patients